Acne - Systemic Pharmacologic Therapies

Systemic Treatments for Acne Introduction Acne that doesn't respond to topical treatments requires systemic (oral) medications. The main systemic approaches fall into three categories: antibiotics, oral retinoids (specifically isotretinoin), and hormonal therapies. Each has distinct mechanisms, appropriate use cases, and important safety considerations. This section focuses on these oral treatments and when to use them. Oral Antibiotics: First-Line Systemic Therapy Doxycycline 100 mg daily and minocycline 100 mg daily are the first-line oral antibiotics for moderate to severe inflammatory acne. These tetracyclines work by reducing Cutibacterium acnes (formerly Propionibacterium acnes) colonization and decreasing bacterial-driven inflammation. Duration Limits and Resistance Prevention Here's a critical point: courses should be limited to ≤3 months (or 12 weeks maximum). This is not arbitrary—it's a guideline designed to prevent antibiotic resistance. Widespread use of oral antibiotics over decades has led to significant increases in Cutibacterium acnes resistance. This resistance is a real clinical problem: resistant strains reduce treatment efficacy, leaving patients with fewer options. Because of this concern, current guidelines increasingly recommend favoring non-antibiotic options (like hormonal therapies or isotretinoin) whenever possible, especially for long-term management. Why the time limit? Prolonged antibiotic use selects for resistant bacteria. By limiting courses to 3 months, we reduce this selective pressure while still allowing time for improvement. If a patient needs longer-term systemic therapy, the conversation should shift toward hormonal approaches rather than extending antibiotics. Oral Isotretinoin: The Powerful Option for Severe Acne Isotretinoin is a systemic retinoid derived from vitamin A that represents one of the most effective treatments for acne, capable of producing long-term remission or permanent clearance. When to Use Isotretinoin Isotretinoin is reserved for: Severe nodulocystic acne (the most severe acne type, producing deep cysts and nodules) Acne unresponsive to conventional therapy (including antibiotics and hormonal agents) Patients with significant scarring risk The reason for these strict indications is isotretinoin's serious adverse effects, which we'll discuss next. Mechanism of Action Isotretinoin works differently than antibiotics—it doesn't kill bacteria. Instead, it dramatically reduces sebum production (up to 90%), normalizes follicular keratinization, and decreases inflammation. Because it addresses underlying sebum overproduction (a fundamental acne pathogen), it can produce long-lasting improvement even after treatment stops. Critical Safety Issue: Teratogenicity Isotretinoin is extremely teratogenic. Even low doses can cause serious birth defects in male fetuses (including hypospadias and underdevelopment of external genitalia) and female fetuses (including cleft palate, cardiac defects, and CNS malformations). For this reason: Isotretinoin is absolutely contraindicated in pregnancy Strict contraceptive measures are mandatory for all females of reproductive potential taking isotretinoin The iPLEDGE program is a mandatory risk evaluation and mitigation strategy (REMS) in the United States that requires: Monthly pregnancy tests for females of childbearing potential Documentation of two forms of contraception Monthly check-ins with prescribers Signed informed consent acknowledging teratogenic risks Other Adverse Effects Beyond teratogenicity, isotretinoin commonly causes: Mucocutaneous dryness: Dry skin, lips, and mucous membranes are nearly universal Hypertriglyceridemia: Elevated triglycerides occur in 25%–50% of patients; this requires baseline lipid testing and periodic monitoring Potential mood changes: There's an association between isotretinoin use and depression, though causality remains debated Hepatotoxicity risk: Liver enzymes must be monitored Because of these effects, isotretinoin requires baseline laboratory work (liver enzymes, lipid panel, pregnancy test if applicable) and regular monitoring throughout therapy. Hormonal Therapies for Acne in Women Hormonal therapy targets a fundamental driver of adult female acne: androgen excess (or androgen sensitivity). While males with acne have baseline androgen production that drives sebaceous gland activity, women with persistent acne often have either elevated androgens or increased androgen sensitivity. How Hormonal Therapy Works Hormonal agents reduce acne through several mechanisms: Decreased sebum production (androgens directly stimulate sebaceous glands) Reduced inflammatory lesions Normalization of follicular keratinization Hormonal therapy is particularly effective in women whose acne worsens with menstrual cycles, a sign of hormonally-driven disease. Combined Oral Contraceptive Pills (COCPs) COCPs contain an estrogen and a progestin. They reduce acne by: Lowering ovarian androgen production (estrogen suppresses LH, which stimulates ovarian testosterone synthesis) Reducing free androgen levels (estrogen increases sex hormone-binding globulin, which binds androgens and reduces the free, biologically active fraction) Net result: Decreased sebum production and fewer inflammatory lesions Which formulations are best? Not all progestins are equal. This is a common source of confusion: First-generation progestins (norethindrone, norgestrel) are androgenic—they can worsen acne and should be avoided Third- and fourth-generation progestins (desogestrel, dienogest, drospirenone, norgestimate) have strong anti-androgenic effects and are preferred for acne Drospirenone and norethindrone are particularly effective Efficacy: Studies show a 40%–70% reduction in acne lesions with combined pills containing anti-androgenic progestins. Added benefit: COCPs are especially useful when patients have both acne and menstrual irregularities or hirsutism, as they address both issues. Anti-Androgenic Agents These medications block androgen action at the receptor level, providing another mechanism to reduce acne. Spironolactone (50–200 mg/day) An aldosterone antagonist that blocks androgen receptors at higher doses Most frequently prescribed antiandrogen for acne Efficacy is dose-dependent: reduces acne by 33%–85% in women Works best when combined with a COCP (to manage menstrual irregularities) Safety consideration: Can cause hyperkalemia; baseline potassium should be assessed and monitored, especially in patients on ACE inhibitors or NSAIDs Cyproterone acetate More potent anti-androgen than spironolactone Often combined with estrogen to prevent menstrual irregularities Produces 75%–90% reduction in acne within three months Less available in some countries (e.g., United States) compared to spironolactone Flutamide A non-steroidal androgen receptor antagonist Can cause hepatotoxicity (liver damage); liver enzymes must be monitored carefully Because of hepatotoxicity risk, it's less commonly used than spironolactone or cyproterone acetate Clascoterone (newer option) A topical anti-androgen approved in 2020 Advantages: Effective without systemic absorption, so it avoids systemic anti-androgenic side effects Represents a promising alternative to systemic anti-androgens for some patients 5α-Reductase Inhibitors These medications block the enzyme 5α-reductase, which converts testosterone to dihydrotestosterone (DHT)—the more potent androgen. By reducing DHT production, they decrease androgen-driven acne. Finasteride and dutasteride have been used in refractory cases of hyperandrogenic acne. However, their use in women is limited because: They have strong teratogenic potential for male fetuses (cause feminization and hypospadias) Women of childbearing potential must use reliable contraception They're generally reserved for cases where other treatments have failed Indications and Contraindications for Hormonal Therapy Indications: Persistent acne in adult women Acne that worsens with menstrual cycles Concomitant hirsutism or androgenic alopecia Polycystic ovary syndrome (PCOS) with acne Contraindications: Pregnancy and breastfeeding (anti-androgens have teratogenic potential; COCPs may reduce milk supply) Thromboembolic risk (for COCPs specifically): history of DVT, PE, thrombophilia, or migraine with aura Severe hepatic disease Uncontrolled hypertension (relative contraindication for spironolactone) Safety Monitoring and Adverse Effects Summary Oral Antibiotics Photosensitivity: Doxycycline increases sun sensitivity; patients need sun protection Gastrointestinal upset: Common, especially on an empty stomach Rare but serious: Clostridioides difficile infection, lupus-like syndrome (minocycline) Isotretinoin Requires baseline and periodic monitoring of: Liver enzymes (hepatotoxicity risk) Lipid panel (hypertriglyceridemia risk) Pregnancy test (monthly, if applicable) Monthly clinical check-ins mandatory through iPLEDGE program Hormonal Therapies COCPs: Monitor for thromboembolic symptoms; counsel on contraceptive efficacy not guaranteed Spironolactone: Check baseline and periodic potassium levels; avoid in patients with renal impairment or on other drugs that elevate potassium Flutamide: Monitor liver enzymes regularly due to hepatotoxicity risk Anti-androgens generally: May cause menstrual irregularities (especially spironolactone alone); best combined with COCPs <extrainfo> Additional Context: Antibiotic Alternatives and Current Treatment Paradigm Shift The guideline recommendation to limit antibiotics to 3 months and favor non-antibiotic options represents a paradigm shift in acne management. This reflects growing concern about antibiotic resistance and the recognition that other modalities (hormonal therapy, isotretinoin, non-antibiotic topicals) may be equally or more effective for long-term control. </extrainfo>